ダウンロード数: 211
このアイテムのファイル:
ファイル | 記述 | サイズ | フォーマット | |
---|---|---|---|---|
j.reth.2019.04.004.pdf | 871.12 kB | Adobe PDF | 見る/開く |
タイトル: | Insights into the biology of fibrodysplasia ossificans progressiva using patient-derived induced pluripotent stem cells |
著者: | Nakajima, Taiki Ikeya, Makoto https://orcid.org/0000-0002-3930-8032 (unconfirmed) |
著者名の別形: | 中島, 大輝 池谷, 真 |
キーワード: | Fibrodysplasia ossificans progressiva Induced pluripotent stem cell Disease modeling Drug discovery Rapamycin |
発行日: | Dec-2019 |
出版者: | Elsevier BV |
誌名: | Regenerative Therapy |
巻: | 11 |
開始ページ: | 25 |
終了ページ: | 30 |
抄録: | The demand for development of new drugs remains on the upward trend because of the large number of patients suffering from intractable diseases for which effective treatment has not been established yet. Recently, several researchers have attempted to apply induced pluripotent stem cell (iPSC) technology as a powerful tool for studying the mechanisms underlying the onset of various diseases and for new drug screening. This technology has made an enormous breakthrough, since it permits us to recapitulate the disease phenotype in vitro, outside of the patient's body. Here, we discuss the latest findings that uncovered a mechanism underlying the pathology of a rare genetic musculoskeletal disease, fibrodysplasia ossificans progressiva (FOP), by modeling the phenotypes with FOP patient-derived iPSCs, and that discovered promising candidate drugs for FOP treatment. We also discussed future directions of FOP research. |
著作権等: | © 2019, The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
URI: | http://hdl.handle.net/2433/241596 |
DOI(出版社版): | 10.1016/j.reth.2019.04.004 |
PubMed ID: | 31193176 |
出現コレクション: | 学術雑誌掲載論文等 |
このリポジトリに保管されているアイテムはすべて著作権により保護されています。